CBCRA
Canadian Breast Cancer Research Alliance
ACRCS
Alliance canadienne pour la recherche sur le cancer du sein
:
Search:
Advanced Search

Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

Show simple item record

dc.contributor.author Narod, S. A.
dc.contributor.author Risch, H.
dc.contributor.author Moslehi, R.
dc.contributor.author Dørum, A.
dc.contributor.author Neuhausen, S.
dc.contributor.author Olsson, H.
dc.contributor.author Provencher, D.
dc.contributor.author Radice, P.
dc.contributor.author Evans, G.
dc.contributor.author Bishop, S.
dc.contributor.author Brunet, J. -S.
dc.contributor.author Ponder, B. A. J.
dc.date.accessioned 2010-01-08T19:40:59Z
dc.date.available 2010-01-08T19:40:59Z
dc.date.issued 1998-08-13
dc.identifier.citation Narod, S.A., Risch, H., Moslehi, R., Dorum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., Brunet, J.S. & Ponder, B.A. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339, 424-8 (1998). en_US
dc.identifier.uri http://hdl.handle.net/1807.1/825
dc.description http://content.nejm.org en_US
dc.description This article is hosted on a website external to the CBCRA Open Access Archive. Selecting "view/open" will launch the full-text article in another browser window. en_US
dc.description.abstract BACKGROUND: Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer. METHODS: We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case-control study. All the patients carried a pathogenic mutation in either BRCA1 (179 women) or BRCA2 (28 women). The control women were enrolled regardless of whether or not they had either mutation. Lifetime histories of oral-contraceptive use were obtained by interview or by written questionnaire and were compared between patients and control women, after adjustment for year of birth and parity. RESULTS: The adjusted odds ratio for ovarian cancer associated with any past use of oral contraceptives was 0.5 (95 percent confidence interval, 0.3 to 0.8). The risk decreased with increasing duration of use (P for trend, <0.001); use for six or more years was associated with a 60 percent reduction in risk. Oral-contraceptive use protected against ovarian cancer both for carriers of the BRCA1 mutation (odds ratio, 0.5; 95 percent confidence interval, 0.3 to 0.9) and for carriers of the BRCA2 mutation (odds ratio, 0.4; 95 percent confidence interval, 0.2 to 1.1). CONCLUSIONS: Oral-contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene. en_US
dc.description.provenance Submitted by Kelly Lee (klee@cbcra.ca) on 2010-01-08T19:40:59Z No. of bitstreams: 1 Narod_August 13 1998.html: 459 bytes, checksum: a89c688136dd31c9b3c6a7c62b5428a5 (MD5) en
dc.description.provenance Made available in DSpace on 2010-01-08T19:40:59Z (GMT). No. of bitstreams: 1 Narod_August 13 1998.html: 459 bytes, checksum: a89c688136dd31c9b3c6a7c62b5428a5 (MD5) Previous issue date: 1998-08-13 en
dc.language.iso en en_US
dc.publisher Massachusetts Medical Society en_US
dc.title Oral Contraceptives and the Risk of Hereditary Ovarian Cancer en_US
dc.type Article en_US

Files in this item

Files Size Description Format View
Narod_August 13 1998.html 459bytes HTML View/Open

This item appears in the following category

Show simple item record

Browse

Tools